May 16, 2024
Exciting news for the Angelman syndrome community! Ionis’ Angelman syndrome program, ION582, has just shared positive preliminary results from the Phase 1/2a HALOS clinical trial. Ionis will be providing an update at the upcoming Angelman Syndrome Foundation meeting in July. […]
Read more
April 15, 2024
See a letter to the Angelman community. Ultragenyx reported positive interim data from the ongoing Phase 1/2 study in patients living with deletion genotype Angelman syndrome after treatment with investigational GTX-102. From company press release: “The totality of these […]
Read more
March 7, 2024
Washington D.C., – The Angelman Syndrome Foundation (ASF) and the Foundation for Angelman Syndrome Therapeutics (FAST) are hosting the inaugural Angelman Syndrome (AS) Congressional Advocacy Day in Washington, D.C. Angelman syndrome advocates from all corners of the country will head […]
Read more
January 13, 2024
The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children’s to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder. The clinic is led by Cesar Ochoa-Lubinoff, MD, MPH, director of […]
Read more